Patient Enrollment Concluded Early in PEGASUS Phase 3 Pemphigus Trial for Rilzabrutinib
Principia Biopharma Inc., a Sanofi company, has successfully completed patient enrollment for the global Phase 3 PEGASUS trial of rilzabrutinib, an investigational treatment for pemphigus, ahead of schedule. The trial aims to evaluate the efficacy and safety of rilzabrutinib in achieving durable complete remission in patients with moderate to severe pemphigus.
© Copyright 2025. All Rights Reserved by MedPath